Federation des caisses Desjardins du Quebec’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
Other funds holding NTLA
RP
Federation des caisses Desjardins du Quebec's NTLA Position: Q2 2026 in Review
Federation des caisses Desjardins du Quebec held its Intellia Therapeutics (NTLA) position steady in Q2 2026 at 1,675 shares worth $28.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2089.
Federation des caisses Desjardins du Quebec first reported a position in NTLA in Q4 2017 and has held it in 19 quarters since. The position peaked at $82.6K in Q2 2023. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.
- Federation des caisses Desjardins du Quebec held 1,675 shares of Intellia Therapeutics worth $28.3K as of Q2 2026.
- Federation des caisses Desjardins du Quebec left its Intellia Therapeutics share count unchanged in Q2 2026.
- Intellia Therapeutics made up ﹤0.01% of Federation des caisses Desjardins du Quebec's portfolio in Q2 2026, its #2089 holding.
- Federation des caisses Desjardins du Quebec first reported a position in Intellia Therapeutics in Q4 2017 and has held it in 19 quarters since.
- Federation des caisses Desjardins du Quebec's Intellia Therapeutics position peaked at $82.6K in Q2 2023.
- 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.
Based on Federation des caisses Desjardins du Quebec's 13F filing for Q2 2026, filed 14 Aug 2026.